Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Open Access
- 1 June 2008
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (6), 930-933
- https://doi.org/10.3324/haematol.12206
Abstract
Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×109/L) and complete responses (platelet count > 100×109/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3–18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.Keywords
This publication has 18 references indexed in Scilit:
- Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adultsHaematologica, 2007
- Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraBlood, 2007
- Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisAnnals of Hematology, 2007
- Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopeniaExperimental Hematology, 2006
- Pharmacokinetic Behavior of RituximabTherapeutic Drug Monitoring, 2005
- Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophiliaBlood, 2004
- Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsBlood, 2004
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Efficacy and safety of rituximab in type II mixed cryoglobulinemiaBlood, 2003
- Rituximab for the treatment of refractory autoimmune hemolytic anemia in childrenBlood, 2003